Longevity & Aging · Supplements
quercetin decreases senescent cell burden
In plain terms: Does quercetin clear out senescent 'zombie' cells?
Contested Longevity & Aging 🐭 Non-human evidence🔬 Includes disconfirming
Part of: 🧪 quercetin
RefutedContestedStrong support
consensus score 0.14
Nearly all the research gave quercetin together with a chemotherapy drug, dasatinib, so it can't tell you what quercetin did alone. Tested on its own, results are split, including a clean negative in human cells. No completed trial has measured this properly in people.
📅 Last reviewed: 2026-07-26 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
9 support 2 contradict 0 tested null 29 mixed · 40 sources, 11 independent groups
What the evidence shows
The attribution problem is the whole story. The great majority of studies measuring senescent-cell burden dose DASATINIB + QUERCETIN together, and a D+Q result cannot be assigned to quercetin — those are recorded here as mixed for exactly that reason.
The evidence (40)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ahn H et al 2026 · study_type: animal | animal | supports | moderate | QUERCETIN ALONE (oral chow, no dasatinib) reduced p21+/p16+ senescent-cell counts and macrophage markers in irradiated (35Gy) mouse skin at 150 days post-irradiation vs control chow; its methylated metabolite (3-O-methylquercetin) reproduce |
| Xia X et al 2026 · study_type: animal | animal | mixed | moderate | D+Q in high-fat-diet (and palmitate-diet) mice significantly reduced hippocampal senescent cell burden (SA-beta-gal+ cells), suppressed p16, and normalized SASP factors, restoring cognitive function and synaptic protein expression. Combinat |
| Hickson LJ et al 2019 · EBioMedicine | observational | mixed | moderate | D+Q COMBINATION (Mayo Clinic / Kirkland-Tchkonia group): open-label phase 1 pilot in 9 diabetic-kidney-disease patients (68.7+-3.1y) given dasatinib 100mg + quercetin 1000mg for 3 days showed reduced adipose p16INK4A+/p21CIP1+ and SA-beta-g |
| Su H et al 2026 · study_type: animal | animal | mixed | moderate | DQ (dasatinib+quercetin) cleared senescent ovarian cells and reduced SASP in cyclophosphamide-induced premature-ovarian-insufficiency mice, restoring estrous cyclicity in 60% of CY+DQ mice vs ~15% of CY-alone mice (p<0.0001) and increasing |
| Tripathi U et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Human senescent HUVECs treated with QUERCETIN ALONE (and, in a separate arm, senescent preadipocytes treated with dasatinib alone) had 30-70% of cells killed (senolytic-sensitive), while the resistant remainder retained lower pro-inflammato |
| Orr M et al 2023 · preprint | observational | mixed | low | D+Q COMBINATION (companion report of the same 5-patient AD pilot cohort as the Nature Medicine trial above): CSF IL-6/GFAP significantly increased (t(4)=3.913 p=0.008; t(4)=3.354 p=0.028) with only a non-significant trend toward higher Abet |
| Iswarya BR et al 2025 · study_type: in-vitro | in-vitro | supports | low | QUERCETIN ALONE (QCT, tested separately from hesperidin/HDN, not combined): in 5-fluorouracil-induced senescent A549 lung adenocarcinoma cells, quercetin significantly reversed SASP-mediated chemoresistance and inhibited migration, with X-G |
| Battaglia-Vieni A et al 2025 · study_type: animal | animal | contradicts | low | D+Q COMBINATION: in a murine folic-acid-induced acute kidney injury model, D+Q pretreatment did NOT reduce the number of senescent p21-positive cells in injured kidneys versus untreated (similar counts), and instead increased Cdkn1a/p21, Lc |
| Rashmi R et al 2026 · study_type: animal | animal | mixed | low | Systematic review/meta-analysis of 24 preclinical studies (570 animals): quercetin, alone or in combination, reduced fibrotic scores and inflammatory/oxidative markers in lung-fibrosis models, but the authors state its senolytic potential ' |
| Needy T et al 2025 · study_type: in-vitro | in-vitro | contradicts | low | QUERCETIN ALONE: 10uM quercetin applied to serially-subcultured (senescent) human mesenchymal stem cells in vitro did NOT show a consistent senolytic effect by SA-beta-gal and live/dead staining, hindered short-term proliferation in some do |
| Tripathi U et al 2025 · bioRxiv | in-vitro | supports | low | QUERCETIN ALONE (tested in human umbilical vein endothelial cells, separately from dasatinib which was tested in preadipocytes): quercetin eliminated the senolytic-sensitive fraction of senescent HUVECs (consistent with senolytics' typical |
| Kecskés S et al 2026 · bioRxiv | animal | mixed | moderate | Preprint: in aged rats with carotid stenosis plus induced ischemic stroke, chronic dasatinib+quercetin treatment reduced immunocytochemistry-assessed cerebrovascular senescent-cell burden, enhanced angiogenesis, and attenuated infarct size/ |
| Tao Z et al 2026 · study_type: animal | animal | supports | low | QUERCETIN ALONE (no dasatinib) reduced SA-beta-gal+ cells and rescued lifespan/locomotion in manganese-exposed C. elegans, and reduced beta-gal positivity, p53/p21 activation and oxidative/mitochondrial dysfunction in Mn-exposed PC12 (rat) |
| Novais EJ et al 2026 · study_type: animal | animal | mixed | moderate | Dasatinib+quercetin (DQ) reduced disc-degeneration grade and lowered p19ARF/p21/SASP markers in SM/J mice, while a comparator drug (Navitoclax) did not; in vitro JUN-pathway inhibition in human degenerated NP cells mimicked DQ's senescence/ |
| Battistelli LS et al 2026 · study_type: animal | animal | mixed | low | Dasatinib+quercetin (D&Q, 5+50 mg/kg monthly gavage x10mo, n=24) reduced alveolar bone loss and downregulated Il6/Mmp13 in AGED mice, but failed to prevent bone loss in a separate ligature-induced periodontitis rat model (n=24) -- efficacy |
| Yan L et al 2026 · Circulation | animal | mixed | moderate | D+Q COMBINATION: using p16-CreER;R26-tdT reporter mice after myocardial infarction, dasatinib+quercetin treatment 'selectively eliminated P16+ macrophages and fibroblasts' (directly tracked via the genetic lineage reporter), improving cardi |
| Shee S et al 2026 · study_type: animal | animal | mixed | moderate | A THREE-drug cocktail (dasatinib+quercetin+FISETIN, not D+Q alone) given as TB adjunct therapy prolonged survival and reduced Mtb lung counts/pathology/senescence markers (p21, p16, gammaH2AX, SASP) in B6.Sst1S and aged mice, with greater b |
| Bun M et al 2026 · study_type: animal | animal | mixed | moderate | In aged mice given high-frequency PTH 1-34 (which induced senescent osteoblast-lineage cell accumulation via mTORC1), co-administered dasatinib+quercetin reduced senescent cell burden, improved cortical porosity, and mitigated rapid post-PT |
| Wang H et al 2026 · Journal of advanced research | in-vitro | supports | low | QUERCETIN ALONE: in vitro, quercetin treatment of senescent human tendon stem/progenitor cells (TSPCs) significantly reduced SASP factor secretion and enhanced tenogenic differentiation via inhibited AKT phosphorylation (AKT/NF-kB/NLRP3 axi |
| Olson C et al 2026 · bioRxiv | animal | mixed | moderate | Preprint directly re-testing a prior claim that D+Q is senolytic in a focal cortical dysplasia mouse model: using longitudinal two-photon imaging + EEG at matched dose/timing, found only a modest reduction in ONE senescence marker (senomorp |
| Khan T et al 2026 · study_type: animal | animal | mixed | moderate | Mixed genetic + D+Q COMBINATION approach: in a mouse pilocarpine temporal-lobe-epilepsy model, senolytic treatment (pooling a genetic senolysis model and pharmacological dasatinib+quercetin) produced a 50% reduction in senescent cells, resc |
| Koloko Ngassie ML et al 2026 · study_type: in-vitro | in-vitro | mixed | moderate | In human fetal airway smooth muscle cells under moderate hyperoxia (50% O2), D+Q [250nM+375nM] decreased beta-galactosidase activity, p21 and PAI-1 expression AND caused cell death (true senolysis), distinct from fucoidan (senomorphic, bloc |
| Lv J et al 2026 · study_type: animal | animal | mixed | low | In ovarian-cancer mouse models, the senolytic cocktail dasatinib+quercetin (and, separately, the NF-kB inhibitor resveratrol) alleviated cancer-induced adipose-derived stem cell senescence/adipose ageing, improved glucose tolerance/insulin |
| Keeble AR et al 2026 · study_type: animal | animal | mixed | moderate | D+Q cleared senescent macrophages (SPiDER-SA-beta-gal, single-cell resolution) and reduced muscle atrophy/cartilage degradation after ACL transection in mice, with greater clearance in muscle than cartilage; human ACL-injury/PTOA patients s |
| Hense JD et al 2026 · study_type: animal | animal | mixed | low | D+Q in female mice with diet-induced MASLD attenuated ovarian senescence/inflammation/fibrosis and improved pregnancy rates, but had only limited effect on liver senescence/inflammation genes and liver mass despite MASLD being a liver-drive |
| Tong X et al 2026 · preprint | animal | mixed | low | D+Q COMBINATION: in a cadmium-induced osteocyte-senescence model, eliminating senescent cells with dasatinib plus quercetin 'markedly reduced osteocyte senescence' and improved bone integrity, with added benefit from co-treatment with melat |
| Karadagatla S et al 2026 · study_type: in-vitro | in-vitro | mixed | low | In H2O2 (100uM)-induced senescent BEAS-2B lung epithelial cells, quercetin combined with ARTEMISININ (not dasatinib, not quercetin alone) reduced SA-beta-gal+ cells and the Atm/p53/p16/p21/Bcl-2 axis while suppressing SASP. Effect cannot be |
| Bian X et al 2026 · study_type: animal | animal | mixed | moderate | MAYO CLINIC / Kirkland-Tchkonia group study: D+Q (5+50 mg/kg, 5-day gavage) reduced kidney injury, fibrosis, p16Ink4a senescence and macrophage/senescence-associated inflammation in streptozotocin-diabetic mice and increased alpha-Klotho/Si |
| Yang B et al 2025 · study_type: animal | animal | mixed | low | D+Q COMBINATION: 4-month long-term dasatinib+quercetin treatment in a dry-AMD mouse model (Abca4-/-Rdh8-/-) 'effectively repressed cellular senescence,' lysosomal alkalinization, lipofuscin accumulation and oxidative stress in the RPE, alon |
| Sun SJ et al 2025 · study_type: animal | animal | mixed | low | D+Q COMBINATION: in a GSDME-reintroduction mouse model of abdominal aortic aneurysm, the induced vascular senescence and AAA phenotype was 'abolished by senolytic therapy with dasatinib plus quercetin.' Combination dosing means the effect c |
| Heinrichs DP et al 2026 · study_type: animal | animal | mixed | low | Dasatinib+quercetin applied to senescent human mesenchymal stem cells produced inconsistent osteogenic/adipogenic differentiation and gene/protein expression results in vitro, increased extracellular-vesicle secretion, and showed unquantifi |
| Gonzales MM et al 2023 · Nature medicine | observational | mixed | low | D+Q COMBINATION: open-label phase 1 trial in 5 early-stage AD patients (mean age 76+-5, 12 weeks) found only non-significant 'trending decreases' in senescence-related cytokines/chemokines in CSF, while IL-6 and GFAP significantly increased |
| Zhang M et al 2026 · study_type: animal | animal | mixed | low | In a study primarily about exercise/SIRT1 protecting against atherosclerosis via adipose-tissue aging, senolytic treatment (dasatinib+quercetin) was used as a pharmacological comparator and 'also attenuated eWAT aging and AS progression' -- |
| Naito Y et al 2026 · study_type: animal | animal | supports | low | QUERCETIN ALONE (no dasatinib): a bioavailability-enhanced formulation (EubioQuercetin, EQN) reduced a composite external aging score in aged mice (median 4.5 vs 8, p<0.01) more than conventional quercetin (CQN, moderate reduction), and dow |
| Fujiwara M et al 2025 · study_type: in-vitro | in-vitro | supports | low | QUERCETIN ALONE (tested separately from dasatinib, not combined): in FGFR4-inhibitor(BLU554)-induced senescent pancreatic ductal adenocarcinoma cell lines (PK-1, T3M-4), quercetin significantly reduced cell viability by ATP assay, indicatin |
| Gao F et al 2026 · bioRxiv | animal | mixed | moderate | Preprint: single-cell/spatial profiling of human valve/aortic specimens plus murine models identified senescent fibroblasts driving ECM-dominant cardiovascular disease; senolytic treatment (dasatinib+quercetin OR fisetin) restored ECM archi |
| Liu J et al 2026 · study_type: animal | animal | mixed | low | D+Q COMBINATION: in a rat model of radiation-induced lung injury (single 30Gy dose), DQ treatment decreased senescence markers p53, p21, and p16 and suppressed multiple SASP factors versus irradiation alone, alongside reduced fibrosis/colla |
| Calls-Cobos A et al 2026 · study_type: animal | animal | mixed | moderate | D+Q in DBA/2-mdx (Duchenne) mice: EARLY treatment (3-5mo) reduced senescent cell burden and fibrosis and improved fiber size/contractile force in skeletal muscle; LATE treatment reduced cardiac senescence/fibrosis but did not help skeletal |
| Qiao Y et al 2026 · study_type: animal | animal | supports | moderate | QUERCETIN ALONE (no dasatinib), given either prophylactically (pre-bleomycin) or therapeutically (post-bleomycin) to mice, produced comparable fibrosis reduction, with the preventive regimen better limiting peaks of epithelial damage, ferro |
| Witkowski W et al 2026 · study_type: in-vitro | in-vitro | mixed | low | A synthetic thioquercetin DERIVATIVE, thioQ(OAc)4 (modified quercetin, not natural quercetin, not combined with dasatinib), showed senolytic activity against cisplatin-induced senescent melanoma cells 'in selected experimental settings' -- |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.